Literature DB >> 12686815

Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group.

Axel Heidenreich1, Peter Albers, Michael Hartmann, Sabine Kliesch, Kai-Uwe Kohrmann, Susanne Krege, Philipp Lossin, Lothar Weissbach.   

Abstract

PURPOSE: Nerve sparing retroperitoneal lymph node dissection has been the standard diagnostic and therapeutic approach to clinical stage I nonseminoma. However, the application of prognostic risk factors and introduction of laparoscopy have recently called into question the clinical usefulness of nerve sparing retroperitoneal lymph node dissection. We assessed the therapeutic efficacy and associated complications of this procedure in patients with clinical stage I nonseminomatous germ cell tumor treated at 7 tertiary referral centers to evaluate its role in the modern management of low stage testis cancer.
MATERIALS AND METHODS: Between January 1995 and September 2000, 239 patients with clinical stage I nonseminomatous germ cell tumor underwent nerve sparing retroperitoneal lymph node dissection in standardized fields of dissection. For retrospective analysis patient charts were reviewed. A minor complication did not prolong hospital stay and a major complication prolonged hospitalization for at least 2 days. Early complications developed within the first 30 days after retroperitoneal lymph node dissection and late complications occurred from postoperative day 31 and thereafter.
RESULTS: Nerve sparing retroperitoneal lymph node dissection was performed unilaterally in 209 patients (88.2%) and bilaterally in 30 (11.8%). Median operative time was 214 minutes (range 90 to 395), mean hospital stay was 8 days (range 4 to 39) and mean blood loss was less than 150 ml. A mean of 18.5 lymph nodes (range 9 to 57) were dissected with metastases detected in 67 patients (28%). An average of 2.9 lymph nodes (range 1 to 14) with a mean diameter of 2.6 cm. (range 0.3 to 6.0) showed metastasis. Disease was pathological stage I in 172 patients (71.7%), 52 (17.6%) had 3 or fewer metastatic lymph nodes, and 15 (6.3%) had 4 to 5 and 10 (4.2%) had greater than 5 positive lymph nodes. Minor complications occurred in 14.2% of the cases and major complications were observed in 5.4%. Antegrade ejaculation was preserved in 93.3% of the patients, recurrence developed in 14 (5.8%) and retroperitoneal recurrence was observed in 3 (1.2%), including 1 in field and 2 out field.
CONCLUSIONS: Primary diagnostic and therapeutic nerve sparing retroperitoneal lymph node dissection still has a role in the primary management of clinical stage I nonseminomatous germ cell tumor. Surgery is associated with low morbidity and patient followup is easy and cost-effective due to the concentration on extraretroperitoneal locations. Primary nerve sparing retroperitoneal lymph node dissection is curative in about 70% of clinical stage I nonseminoma cases with a maximum of 3 positive lymph nodes.

Entities:  

Mesh:

Year:  2003        PMID: 12686815     DOI: 10.1097/01.ju.0000060960.18092.54

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  38 in total

Review 1.  Advances in the treatment of testicular cancer.

Authors:  Hans-Georg Kopp; Markus Kuczyk; Johannes Classen; Arnulf Stenzl; Lothar Kanz; Frank Mayer; Michael Bamberg; Jörg Thomas Hartmann
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  [Retroperitoneal lymphadenectomy - pro laparoscopy].

Authors:  L Lusuardi; G Janetschek
Journal:  Urologe A       Date:  2012-05       Impact factor: 0.639

3.  [Retroperitoneal lymphadenectomy - pro robotic].

Authors:  P Albers
Journal:  Urologe A       Date:  2012-05       Impact factor: 0.639

4.  Retroperitoneal lymph node dissection for high-risk stage I and stage IIA seminoma.

Authors:  Zaza Mezvrishvili; Laurent Managadze
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

5.  [Comments on retroperitoneal lymphadenectomy - laparoscopic versus robotic].

Authors:  A Heidenreich
Journal:  Urologe A       Date:  2012-05       Impact factor: 0.639

6.  [Management of complications after residual tumor resection for metastatic testicular cancer].

Authors:  A Lusch; M Zaum; C Winter; P Albers
Journal:  Urologe A       Date:  2014-07       Impact factor: 0.639

Review 7.  Current Concepts in Management of Stage I NSGCT.

Authors:  Puneet Ahluwalia; Gagan Gautam
Journal:  Indian J Surg Oncol       Date:  2016-12-17

Review 8.  Residual tumor resection (RTR).

Authors:  A Lusch; P Albers
Journal:  World J Urol       Date:  2016-12-21       Impact factor: 4.226

Review 9.  [When is surgical resection of metastases in testicular germ cell tumors indicated and is there a scientific basis?]

Authors:  A Heidenreich; P Paffenholz; F Haidl; D Pfister
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

10.  [Results of the randomised phase III study of the German Testicular Cancer Study Group. Retroperitoneal lymphadenectomy versus one cycle BEP as adjuvant therapy for non-seminomatous testicular tumours in clinical stage I].

Authors:  M Hartmann; R Siener; S Krege; H Schmelz; K-P Dieckmann; A Heidenreich; P Kwasny; M Pechoel; J Lehmann; S Kliesch; K-U Köhrmann; R Fimmers; L Weissbach; V Loy; C Wittekind; P Albers
Journal:  Urologe A       Date:  2009-05       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.